Review anchor
Human immunodeficiency virus type 1 Gag protein
SINGLE PROTEIN · Human immunodeficiency virus 1
As of 2026-09-13
Evidence Snapshot
Human immunodeficiency virus type 1 Gag protein
CHEMBL3556
SINGLE PROTEIN
Human immunodeficiency virus 1
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Human immunodeficiency virus type 1 Gag protein as ChEMBL target CHEMBL3556, mapped to UniProt Q77YG1. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3556
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q77YG1
Gag polyprotein
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Human immunodeficiency virus type 1 Gag protein matters
Human immunodeficiency virus type 1 Gag protein is reviewed as Gag polyprotein (UniProt Q77YG1); the current evidence base includes 1 approved drug, 10 compounds, and 7 assays, with lead potency reaching pChEMBL 9.0.
Protein context
Gag polyprotein
Gag polyprotein Sequence length is 500 aa.
Review this target as Human immunodeficiency virus type 1 Gag protein, mapped to UniProt Q77YG1. ChEMBL maps the protein component as Gag polyprotein. Sequence length is 500 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q77YG1
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 1 approved drug, 10 compounds, and 7 assays for this target. The dominant activity type is KD. CHEMBL4594438 is the current potency anchor at pChEMBL 9.0.
Use CHEMBL4594438 as the tractability anchor when discussing potency (pChEMBL 9.0).
Activity source · ChEMBL 36 via Core Engine
1 approved
pChEMBL 9.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Human immunodeficiency virus type 1 Gag protein matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q77YG1, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
10
Total Compounds
7
Total Assays
1
Approved Drugs
KD: 4.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4594438
|
9.0 | Kd | Approved |
|
|
No preferred name
CHEMBL5641856
|
8.6 | Kd | — |
|
|
No preferred name
CHEMBL3827379
|
8.5 | Kd | Clinical |
|
|
No preferred name
CHEMBL4163247
|
8.3 | Kd | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
LENACAPAVIR
CHEMBL4594438
|
2022 |
Source Header